Protalix BioTherapeutics Inc. (PLX): H.C. Wainwright Sees 533% Price Potential!
Reading Time: 2 minutes
Protalix BioTherapeutics Inc. (PLX) is a biopharmaceutical company specialized in the development and manufacturing of recombinant proteins for the treatment of rare and complex diseases. The company utilizes its proprietary ProCellEx technology for protein expression in plant cells and pursues a robust strategy of chemical and genetic modification, including PEGylation. PEGylation is a biochemical process in which a polyethylene glycol (PEG), a water-soluble polymer, is attached to a molecule such as a protein, peptide, or drug. This aims to enhance...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
